Research ArticleResearch Article

Prognostic Factors of Gastrointestinal Stromal Tumors: A Single Institutional Retrospective Experience with Surgical Management over 20 Years

Yong-kai WU, Dong-bing ZHAO, Cheng-feng WANG, Jian-qiang CAI, Yong-fu SHAO and Ping ZHAO
Clinical Oncology and Cancer Research June 2010, 7 (3) 175-180; DOI: https://doi.org/10.1007/s11805-010-0514-z

References

  1. ↵
    1. Bucher P,
    2. Egger JF,
    3. Gervaz P, et al.
    An audit of surgical management of gastrointestinal stromal tumours (GIST). EJSO 2006; 32: 310-314.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Blay JY,
    2. Bonvalot S,
    3. Casali P, et al.
    GIST consensus meeting panelists: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. AnnOncol 2005; 16: 566-578.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Fletcher CD,
    2. Berman JJ,
    3. Corless C, et al.
    Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-465.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Trupiano JK,
    2. Stewart RE,
    3. Misick C, et al.
    Gastric stromal tumors-a clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. Am J Surg Pathol 2002; 26: 705-714.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Nilsson B,
    2. Bümming P,
    3. Meis-Kindblom JM, et al.
    Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103: 821-829.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Song Z,
    2. Wang JL,
    3. Pan YL, et al.
    Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients. Hepatogastroenterology 2009; 56: 149-153.
    OpenUrlPubMed
  7. ↵
    1. Joensuu H.
    Gastrointestinal stromal tumor (GIST). AnnOncol 2006; 17 (Supplement 10): x280-x286.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Crosby JA,
    2. Catton CN,
    3. Davis A, et al.
    Malignant gastrointestinal stromal tumors of the small intestine-a review of 50 cases from a prospective database. AnnSurg Onco1 2001; 8: 50-59.
    OpenUrl
  9. ↵
    1. DeMatteo RP,
    2. Lewis JJ,
    3. Leung D, et al.
    Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. AnnSurg 2000; 231: 51-58.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Pierie JP,
    2. Choudry U,
    3. Muzikansky A, et al.
    The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-389.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Rubin BP,
    2. Heinrich MC,
    3. Corless CL.
    Gastrointestinal stromal tumour. Lancet 2007; 369: 1731-1741.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Basu S,
    2. Balaji S,
    3. Bennett DH, et al.
    Gastrointestinal stromal tumors (GIST) and laparoscopic resection Surg Endosc 2007; 21: 1685-1689.
    OpenUrlPubMed
  13. ↵
    1. Kindblom LG,
    2. Remotti HE,
    3. Aldenborg F, et al.
    Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269.
    OpenUrlPubMedWeb of Science
  14. ↵
    1. Seidal T,
    2. Edvardsson H.
    Expression of c-kit (CDll7) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. Histopathology 1999; 34: 416-424.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Amato GD,
    2. Steinert DM,
    3. McAuliffe JC, et al.
    Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005; 12: 44-56.
    OpenUrlPubMed
  16. ↵
    1. Zalupski M,
    2. Metch B,
    3. Balcerzak S, et al.
    Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83: 926-932.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. van Oosterom AT,
    2. Judson I,
    3. Verweij J, et al.
    Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 358: 1421-1423.
    OpenUrlCrossRefPubMedWeb of Science
    1. Demetri GD,
    2. von Mehren M,
    3. Blanke CD, et al.
    Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
    OpenUrlCrossRefPubMedWeb of Science
    1. Verweij J,
    2. van Oosterom A,
    3. Blay JY, et al.
    Imatinib mesylate (STI-571 ImatinibwGleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-2011.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Verweij J,
    2. Casali PG,
    3. Zalcberg J, et al.
    Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Joensuu H,
    2. Roberts PJ,
    3. Sarlomo-Rikala M, et al.
    Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Dematteo RP,
    2. Ballman KV,
    3. Antonescu CR, et al.
    Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Corless CL,
    2. McGreevey L,
    3. Town A, et al.
    KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. J Mol Diagn 2004; 6: 366-370.
    OpenUrlCrossRefPubMedWeb of Science
    1. Antonescu CR,
    2. Besmer P,
    3. Guo T, et al.
    Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-4190.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Heinrich MC,
    2. Corless CL,
    3. Demetri GD, et al.
    Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords